Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

Zainab M. Elsayed; Haytham O. Tawfik; Loah R. Hemeda; Mohamed S. Nafie; Hadia Almahli; Rehan Monir; Ikhlas A. Sindi; Eslam B. Elkaeed; Mostafa M. Elbadawi; Mahmoud A. El Hassab; Wagdy M. Eldehna

doi:10.1039/d6md00179c

Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

Zainab M. Elsayed
, Haytham O. Tawfik
, Loah R. Hemeda
, Mohamed S. Nafie
, Hadia Almahli
, Rehan Monir
, Ikhlas A. Sindi
, Eslam B. Elkaeed
, Mostafa M. Elbadawi
, Mahmoud A. El Hassab
, Wagdy M. Eldehna

North Wales Medical School

Kafrelsheikh University
Tanta University, Egypt.
Beni-Suef University
University of Sharjah
King Khalid University
King Abdulaziz University
Al‐Azhar University
King Salman International University (KSIU)

Research output: Contribution to journal › Article › peer-review

Abstract

As possible dual VEGFR-2/EGFR inhibitors, a new set of quinazoline-chalcone hybrid compounds (8a–h and 11a–h) was logically developed and synthesized.

Original language	English
Journal	RSC Medicinal Chemistry
Early online date	1 May 2026
DOIs	https://doi.org/10.1039/d6md00179c
Publication status	Published - May 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

VEGFR-2/EGFR inhibitors
Cancer therapeutics
Drug discovery
Medicinal chemistry

Access to Document

10.1039/d6md00179c

Embargoed Document

Manuscript-R1_Clean_
Accepted author manuscript, 1.94 MB
Embargo ends: 01/05/2027 00:00 BST

Cite this

@article{a36a303467f846ab96a6753875edd5e5,

title = "Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors",

abstract = "As possible dual VEGFR-2/EGFR inhibitors, a new set of quinazoline-chalcone hybrid compounds (8a–h and 11a–h) was logically developed and synthesized.",

keywords = "VEGFR-2/EGFR inhibitors, Cancer therapeutics, Drug discovery, Medicinal chemistry",

author = "Elsayed, \{Zainab M.\} and Tawfik, \{Haytham O.\} and Hemeda, \{Loah R.\} and Nafie, \{Mohamed S.\} and Hadia Almahli and Rehan Monir and Sindi, \{Ikhlas A.\} and Elkaeed, \{Eslam B.\} and Elbadawi, \{Mostafa M.\} and \{El Hassab\}, \{Mahmoud A.\} and Eldehna, \{Wagdy M.\}",

year = "2026",

month = may,

doi = "10.1039/d6md00179c",

language = "English",

journal = "RSC Medicinal Chemistry",

issn = "2632-8682",

publisher = "Royal Society of Chemistry (RSC)",

}

TY - JOUR

T1 - Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

AU - Elsayed, Zainab M.

AU - Tawfik, Haytham O.

AU - Hemeda, Loah R.

AU - Nafie, Mohamed S.

AU - Almahli, Hadia

AU - Monir, Rehan

AU - Sindi, Ikhlas A.

AU - Elkaeed, Eslam B.

AU - Elbadawi, Mostafa M.

AU - El Hassab, Mahmoud A.

AU - Eldehna, Wagdy M.

PY - 2026/5

Y1 - 2026/5

N2 - As possible dual VEGFR-2/EGFR inhibitors, a new set of quinazoline-chalcone hybrid compounds (8a–h and 11a–h) was logically developed and synthesized.

AB - As possible dual VEGFR-2/EGFR inhibitors, a new set of quinazoline-chalcone hybrid compounds (8a–h and 11a–h) was logically developed and synthesized.

KW - VEGFR-2/EGFR inhibitors

KW - Cancer therapeutics

KW - Drug discovery

KW - Medicinal chemistry

U2 - 10.1039/d6md00179c

DO - 10.1039/d6md00179c

M3 - Article

SN - 2632-8682

JO - RSC Medicinal Chemistry

JF - RSC Medicinal Chemistry

ER -

Development of novel chalcone-based quinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

Abstract

UN SDGs

Keywords

Access to Document

Embargoed Document

Fingerprint

Cite this